Anti-Inflammatory Strategies in Asthma Management

Asthma is characterised by chronic airway inflammation driven by a complex interplay of immune cells, cytokines and structural remodelling. Standard therapy relies on inhaled corticosteroids and β2-agonists to suppress inflammation and relieve bronchoconstriction, while biologicals targeting type 2 cytokines (IL-4, IL-5, IL-13) have transformed care for severe phenotypes. Emerging strategies focus on repurposing small molecules with immunomodulatory effects, refining inhaled delivery to enhance local activity and reduce systemic exposure, and harnessing regulatory T cells to restore immune tolerance. Personalised regimens aligned to molecular endotypes underpin efforts to improve outcomes across diverse populations and address the global burden of asthma.

Research from Nature Portfolio

Recent preclinical work has demonstrated that inhaled pitavastatin can reduce allergen‐induced airway hyperresponsiveness and eosinophilic inflammation in murine models. Administration by aerosol led to decreased goblet cell hyperplasia and airway wall thickening, accompanied by a shift in T-cell subsets including an increase in CD4+ CD25+ Foxp3+ regulatory T cells. Cytokine profiling revealed reductions in IL-4 and IL-17 alongside elevations in IFN-γ, underscoring a rebalancing of type 2 inflammatory pathways. These findings support direct pulmonary delivery of statins as a targeted anti-inflammatory approach in asthma management.

Anti-Inflammatory Strategies in Asthma Management publication trend

The graph below shows the total number of articles in anti-inflammatory strategies in asthma management across all publications each year (not limited to Nature Index journals).

Technical terms

Airway hyperresponsiveness: Exaggerated bronchoconstrictor response to stimuli.

Statins: HMG-CoA reductase inhibitors with lipid-lowering and immunomodulatory effects.

Regulatory T cells (Tregs): Subset of CD4+ lymphocytes that suppress immune responses and maintain tolerance.

Interleukins: Cytokines that mediate communication between immune cells, notably IL-4, IL-13 and IL-17 in asthma.

Mendelian randomisation: Genetic epidemiology method using inherited variants to infer causality between exposures and outcomes.

Goblet cell hyperplasia: Increase in mucus-secreting cells contributing to airway obstruction.

References

1. Repurposing lipid-lowering drugs on asthma and lung function: evidence from a genetic association analysis. Journal of Translational Medicine (2024).
2. Bioinformatic Analysis of Key Regulatory Genes in Adult Asthma and Prediction of Potential Drug Candidates. Molecules (2023).
3. Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing. Cells (2022).
4. Anti-asthmatic effect of pitavastatin through aerosol inhalation is associated with CD4+ CD25+ Foxp3+ T cells in an asthma mouse model. Scientific Reports (2017).